ReviewFrontiers in cell and developmental biology2021
Hyperphosphatemia and Cardiovascular Disease.
Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Association between blood phosphorus level and clinical outcomes in critically ill patients: A systematic review and meta-analysis.JPEN. Journal of parenteral and enteral nutrition · 2026Pooled it
- Efficacy and safety of tenapanor vs placebo in treating CKD patients on dialysis and with hyperphosphatemia: a systematic review and meta-analysis of 2251 patients.International urology and nephrology · 2025Pooled it
- High Serum Phosphate Is Associated with Cardiovascular Mortality and Subclinical Coronary Atherosclerosis: Systematic Review and Meta-Analysis.Nutrients · 2024Pooled it
- The efficacy and safety of cuttlebone for lowering serum phosphate in patients with end-stage renal disease: a meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2023Pooled it
- Phosphate: An Anion Controlling Metabolic Functions.Nutrients · 2026Review
- Clinical Evaluation of Low-Dose Magnesium Carbonate as a Phosphate Binder in Chronic Hemodialysis Patients.Life (Basel, Switzerland) · 2026Article
- Cardiovascular Disease Management Consensus in Kidney Transplantation Recipients.Acta Cardiologica Sinica · 2026Article
- TMEM174 Deficiency Reduces Longevity by Promoting Phosphate-Driven Vascular Calcification.Research square · 2026Article
- Review
- Analysis of Phosphate Transporters in Peritoneal Cells and Tissues and Their Transport Kinetics In Vitro.International journal of molecular sciences · 2026Article
- TMEM174 Deficiency Reduces Longevity by Promoting Phosphate-Driven Vascular Calcification.bioRxiv : the preprint server for biology · 2026Article
- Review
- From Biomarkers to Biosensors: Transforming Comorbidity Management in Dialysis Care.Sensors (Basel, Switzerland) · 2026Review
- Serum Levels of Calcium, Phosphate, and Vitamin D and Incident Arrhythmias: A Prospective Cohort Study of 348,094 UK Biobank Participants.Nutrients · 2025Article
- Dysregulation of mineral metabolism: association of albumin-corrected calcium and vitamin D with diabetic kidney disease in type 2 diabetes-a cross-sectional study.European journal of medical research · 2025Article
- Dietary Phosphorus and Metabolic Health in CKD and ESKD.Clinical journal of the American Society of Nephrology : CJASN · 2025Review
- Liposomal Delivery of Allolobophora caliginosa Coelomic Fluid Attenuates Myocardial Infarction by Suppressing Oxidative Damage, Inflammation, and Apoptosis.Applied biochemistry and biotechnology · 2025Article
- Soft tissue calcifications in chronic kidney disease-beyond the vasculature.Pflugers Archiv : European journal of physiology · 2025Review
- Cholestyramine in hemodialysis: a new approach for hyperphosphatemia management.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025Article
- Association between serum α-klotho levels and the incidence of diabetic kidney disease and mortality in type 2 diabetes: evidence from a Chinese cohort and the NHANES database.Diabetology & metabolic syndrome · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperphosphatemia or even serum phosphate levels within the "normal laboratory range" are highly associated with increased cardiovascular disease risk and mortality in the general population and patients suffering from chronic kidney disease (CKD). As the kidney function declines, serum phosphate levels rise and subsequently induce the development of hypertension, vascular calcification, cardiac valvular calcification, atherosclerosis, left ventricular hypertrophy and myocardial fibrosis by distinct mechanisms. Therefore, phosphate is considered as a promising therapeutic target to improve the cardiovascular outcome in CKD patients. The current therapeutic strategies are based on dietary and pharmacological reduction of serum phosphate levels to prevent hyperphosphatemia in CKD patients. Large randomized clinical trials with hard endpoints are urgently needed to establish a causal relationship between phosphate excess and cardiovascular disease (CVD) and to determine if lowering serum phosphate constitutes an effective intervention for the prevention and treatment of CVD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.